Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
01 mai 2021 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
30 avr. 2021 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces New Appointment to Board of Directors
05 avr. 2021 06h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
02 mars 2021 06h00 HE
|
Oyster Point Pharma, Inc.
Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss...
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
25 févr. 2021 16h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
18 févr. 2021 16h01 HE
|
Oyster Point Pharma, Inc.
OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020Phase...
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
12 févr. 2021 09h14 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
29 déc. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
18 déc. 2020 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
07 déc. 2020 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...